Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
220 participants
INTERVENTIONAL
2025-08-01
2029-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Are there differences in the light response in patients with delayed sleep-wake phase disorder? Does citalopram increase melatonin suppression in patients with delayed sleep-wake phase disorder?
Participants will complete activity and melatonin testing at home to determine their circadian timing. This will be followed by an eye test looking at the pupil response to different light stimuli. A subset of participants will complete two inpatient admissions where melatonin levels will be sampled and they will be exposed to a bright light. During one round of testing they will receive a placebo and in the other round of testing they will take a single dose of citalopram, a selective serotonin reuptake inhibitor.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pathophysiology of Circadian Rhythm Delayed Sleep Wake Phase Disorder
NCT06471374
Circadian Rhythms and Sleep in Familial DSPS and ASPS
NCT00246454
Cardiometabolic Outcomes With Light Exposure During Sleep
NCT05317559
Sleep, Wake and Light Therapy for Depression
NCT03405493
Neural Mechanisms Underlying the Antidepressant Effects of Sleep Deprivation
NCT03169543
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DSWPD
Placebo or Citalopram followed by bright light (all participants will receive both interventions in random order).
Light and Citalopram
Participants will receive placebo or citalopram, followed by bright light exposure
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Light and Citalopram
Participants will receive placebo or citalopram, followed by bright light exposure
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* History of eye disease or eye surgery
* Unstable medical or psychiatric condition
* Shift work or self imposed irregular sleep schedules
* Caffeine consumption \>400mg/day
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Northwestern University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sabra Abbott
Professor
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STU00221304
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.